Citations

Clear

13603 citation(s) found for "_, _".

Catatonia in the Medically ILL: Etiology, Diagnosis, and Treatment. The Academy of Consultation-Liaison Psychiatry Evidence-Based Medicine Subcommittee Monograph
Denysenko, Lex , Sica, Nicole, Penders, Thomas M. , Philbrick, Kemuel L. , Walker, Audrey, Shaffer, Scott, Zimbrean, Paula C. , Freudenreich, Oliver , Rex, Nicole, Carroll, Brendan T. , Francis, Andrew

Mayo Clinic

Annals of Clinical Psychiatry | September 11, 2025 | Volume: 30 | Issue: 2 | Pages: 140-155

10.1177/104012371803000209 Get It

Background Catatonia in medically ill patients is rare but often unrecognized. This monograph summarizes current knowledge on the diagnosis, epidemiology, etiology, and management of catatonia occurring in the medical setting. Methods PubMed searches were used to identify relevant articles from 1962 to present. Results More than 3,000 articles were obtained and reviewed for relevance, including references of articles identified by the initial search. Several areas were identified as important, including: (1) catatonia and delirium; (2) malignant catatonia; (3) pediatric catatonia; (4) catatonia associated with another medical condition (CAMC); (5) drug exposure and withdrawal syndromes associated with catatonia; and (6) treatment of catatonia in the medical setting. Conclusions Catatonia in the medically ill appears to have numerous etiologies, although etiology does not seem to modify the general treatment approach of prompt administration of lorazepam. Delirium and catatonia are commonly comorbid in the medical setting and should not be viewed as mutually exclusive. Electroconvulsive therapy should be offered to patients who do not respond to benzodiazepines or have malignant features. Removing offending agents and treating the underlying medical condition is paramount when treating CAMC. Memantine or amantadine may be helpful adjunctive agents. There is not enough evidence to support the use of antipsychotics or stimulants in treating CAMC.
Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Targeted Review of Clinical Presentation, Diagnosis, and Approaches to Psychopharmacologic Management
Jeffrey, Jessica , Dearlove, Joanna, IsHak, Waguih William , Brooks, John O. , Kruse, Jennifer L. , Davis, Michael C.

Mayo Clinic

Annals of Clinical Psychiatry | September 11, 2025 | Volume: 26 | Issue: 2 | Pages: 111-119

10.1177/104012371402600205 Get It

Background Anti- N -methyl-D-aspartate receptor (anti-NMDAR) encephalitis was formally described in 2007 and includes a range of psychiatric and neurologic symptoms. Most patients with anti-NMDAR encephalitis initially present to psychiatrists for diagnosis and treatment. However, there is limited literature summarizing treatment strategies for psychiatric symptoms. In an effort to improve identification and treatment, this review article provides an overview of anti-NMDAR encephalitis, with a focus on psychopharmacologic treatment strategies. Two case reports provide a clinical context for the literature review. Methods The authors conducted a PubMed search. Results Prominent psychiatric symptoms of anti-NMDAR encephalitis include psychosis, agitation, insomnia, and catatonia. Neuroleptics may be helpful for managing psychosis and agitation, but may exacerbate movement abnormalities. Diphenhydramine and benzodiazepines are helpful for agitation and insomnia. In addition, the anticholinergic affinity of diphenhydramine can improve dystonia or rigidity attributable to anti-NMDAR encephalitis, while benzodiazepines and electroconvulsive therapy have been used for catatonia associated with this condition. Conclusions Psychiatrists play an important role in the diagnosis and treatment of anti-NMDAR encephalitis. Recognizing the typical clinical progression and closely monitoring for accompanying neurologic symptoms will facilitate diagnosis and timely treatment. Careful selection of psycho-pharmacological interventions may reduce suffering.
Eliminating Disparities in Otolaryngology Resident Application Selection
Bukowski, Emily E. K. , Bisco, Susan E. , Carducci, Valentina , Stokken, Janalee K. , Yin, Linda X , Bayan, Semirra L. , Carlson, Matthew L , Yin, Linda X. , Romero‐Brufau, Santiago

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | September 11, 2025 | Volume: 135 | Issue: 2 | Pages: 101-107

10.1177/00034894251363745 | PMID 40931850 Get It

Objective: To develop, implement, and evaluate a novel process used for residency application review that deemphasizes metrics known to create bias with the goal of interviewing and matching a more diverse resident cohort. Methods: Between 2020 and 2023, a novel standardized rubric and application review process were developed and implemented at the authors’ academic training program. The rubric deemphasized USMLE scores, honor society membership, and number of publications while utilizing an AI-driven pre-sort of applications, facilitating holistic review. This weighted applicant attributes identified in personal statements, life experiences, achievements in community, leadership roles, otolaryngology-specific impressions highlighted in letters of recommendation, and otolaryngology-specific research and publications similarly to academic metrics (clerkship grades and standardized test scores). Demographics of applicants interviewed and matched into our program were compared pre- and post-implementation using descriptive statistics. Results: Using a standardized rubric to review residency applications that deemphasizes traditional metrics, the authors’ otolaryngology residency program has interviewed, ranked, and matched more diverse candidates. As a result, from 2019 to 2022, the overall resident cohort has diversified from 4% historically marginalized residents to 24%, from 28% female residents to 44%, and from 33% of residents outside our geographic region to 66%. Conclusion: There is significant underrepresentation among otolaryngology residents. Selection based upon USMLE Step 1 scores, honor society membership, and number of publications have been shown to restrict diversity. Purposeful holistic review increases diversity in interviewed and matched resident cohort.
Extended analgesia, enhanced recovery: optimizing outcomes after total knee arthroplasty with continuous adductor canal block
D’Souza, Ryan S. , Gleicher, Yehoshua , Labandeyra, Hipólito , D'Souza, Ryan S

Mayo Clinic

Regional Anesthesia & Pain Medicine | September 11, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-107146

10.1136/rapm-2025-107146 | PMID 40935406 Get It

Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Benson, Al B. , D’Angelica, Michael I. , Ahmed, Aijaz, Akce, Mehmet , Anaya, Daniel A. , Are, Chandrakanth , Aye, Lydia, Baker, Marshall S., Binder, David C. , Burgoyne, Adam M. , Castellanos, Jason , Cloyd, Jordan M. , Franses, Joseph W. , Harris, William P., Iyer, Renuka , Jennings, Lawrence J. , Kelley, Robin Kate , Khan, Sajid , Palta, Manisha , Sahai, Vaibhav , Stein, Stacey , Stephans, Kevin L. , Thanikachalam, Kannan , Yano, Motoyo , Yopp, Adam C. , Zhao, Ken, Schonfeld, Ryan, Hochstetler, Cindy, Sahai, Vaibhav , Abrams, Thomas A. , Anders, Robert A. , Bachini, Melinda , Brown, Daniel B. , Cullinan, Darren R. , Glazer, Evan S. , Levine, Matthew H , Melstrom, Laleh , Raman, Steven S. , Ronnekleiv-Kelly, Sean M , Turk, Anita , Vauthey, Jean‐Nicolas , Venook, Alan P. , Zhao, Ken

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 10, 2025 | Volume: 23 | Issue: 9 | Pages: 403-418

10.6004/jnccn.2025.0042 | PMID 40930144 Get It

The NCCN Guidelines for Biliary Tract Cancers (BTCs) provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts is convened at least once annually to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. This manuscript focuses on the adjuvant chemotherapy and chemoradiation treatment options for BTCs as well as the systemic treatment recommendations for patients with advanced BTCs.
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 7.2025
Riely, Gregory J. , Wood, Douglas E. , Aisner, Dara L. , Bauman, Jessica R. , Desai, Aakash , Dilling, Thomas J. , Durm, Gregory A. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Levy, Benjamin, Maldonado, Fabien , Morgensztern, Daniel , Mullikin, Trey C. , Ng, Thomas, Owen, Dawn , Patel, Sandip Pravin , Riess, Jonathan W. , Mendez, Ana Lucia Ruano, Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yau, Edwin , Gregory, Kristina M., Hang, Lisa, Desai, Aakash P , Loo, Billy W. , Axtell, Andrea L. , Bharat, Ankit , Chang, Joe Y. , Dowell, Jonathan E. , Grotz, Travis E. , Juloori, Aditya , Lanuti, Michael D. , Lin, Jules , Lovly, Christine Marie , Owen, Dwight H , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 10, 2025 | Volume: 23 | Issue: 9 | Pages: 354-362

10.6004/jnccn.2025.0043 | PMID 40930154 Get It

The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of NSCLC. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines, with a focus on systemic therapy options for the treatment of patients with nonmetastatic NSCLC and the corresponding molecular testing considerations.
It’s Time to Consider How We Should Use Vasopressors, Rather Than Just Which We Should Use
Wieruszewski, Patrick M. , Jabaley, Craig S. , Wieruszewski, Patrick M , Jabaley, Craig S

Mayo Clinic

Critical Care Explorations | September 9, 2025 | Volume: 7 | Issue: 9 | Pages: e1317

10.1097/cce.0000000000001317 | PMID 40924922 Get It

Improvement in Insulin Sensitivity Prevents Decline in Glucose Uptake, Functional Connectivity, and Volume in the Insulin Resistant Human Brain.
Nair, K. Sreekumaran , Klaus, Katherine A. , Sevits, Kyle J., Leija, Robert G. , Kumar, Arathi Prabha, Sinhawansa, Sumaiya, Dreconga, Martina, Carter, Rickey E. , Lowe, Val J. , Pataky, Mark W , Ruegsegger, Gregory, Klaus, Katherine, Sevits, Kyle , Leija, Robert, Kumar, Arathi, Carter, Rickey, Stricker, Nikki, Port, John D , Nair, K Sreekumaran , Carter, Rickey E , Ruegsegger, Gregory N. , Jo, Hang Joon , Lim, Seokbeen , Cobelli, Claudio , Stricker, Nikki H. , Port, John D.

Mayo Clinic

No container title available | September 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7462946/v1 | PMID 40964018 Get It

Abstract Insulin resistance (IR) is a modifiable risk factor for dementia, yet its effects on brain metabolism and function remain unclear. In older adults, greater IR was associated with reduced cerebral glucose uptake (indicating impaired mitochondrial metabolism), atrophy, and weakened connectivity between brain regions critical for cognition. In neuron-specific insulin receptor knockout mice, brain IR produced deficits in hippocampal- and prefrontal-dependent tasks accompanied by reduced brain mitochondrial ATP and elevated reactive oxygen species. To evaluate reversibility of IR-induced brain deficits, forty older adults with IR were randomized to 40-weeks of metformin or placebo. Metformin improved insulin sensitivity, increased brain glucose uptake, strengthened cognitive network connectivity, and preserved whole-brain and regional volumes implicated in decision-making and learning. Metformin also improved processing speed and working memory. Collectively, these findings highlight IR as a driver of brain metabolism and support the concept that insulin sensitization can prevent neurobiological deficits in older people with IR.
Race, Ethnicity, and Antiemetic Management: Reply
Milam, Adam J. , Milam, Adam J , Burton, Brittany N. , Warner, David O.

Mayo Clinic

Anesthesiology | September 9, 2025 | Volume: 143 | Issue: 4 | Pages: 1135-1136

10.1097/aln.0000000000005644 | PMID 40923838 Get It